Pulmonx's revenue growth has decelerated sharply to 6.2% year over year in 2026Q3 at $22.8M, down from 20-23% growth through much of 2024 and early 2025, while operating margin remained at -32.8% and gross margin of 76.2% has not translated into profitability.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 27, 2026 | -$0.19+26.0% vs -$0.26 | $23M+4.1% vs $22M |
Q3 2026 Jul 29, 2026 | -$0.24+14.3% vs -$0.28 | $23M+1.6% vs $22M |
Q2 2026 Apr 29, 2026 | -$0.33+0.0% vs -$0.33 | $21M+0.8% vs $20M |
Q2 2026 Mar 4, 2026 | -$0.25+35.9% vs -$0.39 | $23M+4.0% vs $22M |
REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.34 per share a year ago.
Pulmonx NASDAQ: LUNG reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to expand its market.
Pulmonx Corporation (LUNG) Q3 2026 Earnings Call Transcript
Benchmark LUNG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Pulmonx Corporation (LUNG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.56 | $108.13M | -2.60 | 8.01% | -47.93% | -98.23% | — | |
| $63.98 | $1.84B | 18.38 | 13.6% | 11.43% | 12.49% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — | |
| $20.62 | $1.17B | -10.29 | 37.22% | -32.6% | -33.23% | — | |
| $87.23 | $5.2B | 32.89 | 11.66% | 9.94% | 9.65% | — |
Pulmonx Corporation (LUNG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Pulmonx Corporation (LUNG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 27, 2026·SEC
Jul 29, 2026·SEC
Jun 4, 2026·SEC
Get notified when LUNG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pulmonx Corporation (LUNG) stock FAQ — growth, dividends, profitability & financials explained
Pulmonx Corporation (LUNG) reported $88.8M in revenue over the trailing twelve months. Revenue was $90.5M in fiscal year 2025. That is 352% more than the $20.0M of fiscal year 2018.
Pulmonx Corporation (LUNG) revenue fell by 3.2% over the trailing twelve months, compared with the twelve months before.
No. Pulmonx Corporation (LUNG) reported a net loss of $42.6M over the trailing twelve months.
Pulmonx Corporation (LUNG) had a return on equity (ROE) of -98.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Pulmonx Corporation (LUNG) had negative free cash flow of $25.6M over the trailing twelve months.
